加压腹腔雾化化疗(PIPAC)治疗晚期卵巢癌。文献综述

IF 0.5 4区医学 Q4 OBSTETRICS & GYNECOLOGY

European journal of gynaecological oncology Pub Date : 2022-01-12 DOI:10.31083/j.ejgo4301004

V. Psomiadou, A. Fotiou, A. Prodromidou, C. Iavazzo

{"title":"加压腹腔雾化化疗(PIPAC)治疗晚期卵巢癌。文献综述","authors":"V. Psomiadou, A. Fotiou, A. Prodromidou, C. Iavazzo","doi":"10.31083/j.ejgo4301004","DOIUrl":null,"url":null,"abstract":"Objective: The majority of advanced ovarian cancer (OC) patients do not fully respond to systemic chemotherapy, thus complete cytoreduction can not be achieved in such cases. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been suggested as an alternative approach for these women. Our study aimed to review the literature regarding the application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in OC patients with peritoneal carcinomatosis (PC). Data source: Articles in the English language were searched in PubMed. Search terms included “PIPAC” and “ovarian cancer”. Methods of study selection: The authors evaluated all studies presenting an application of pressurised intraperitoneal aerosol chemotherapy (PIPAC) on ovarian cancer patients. The published guidelines for Systematic Reviews and Meta-analyses (PRISMA) were followed in the present systematic review which was performed based on the authors’ predetermined inclusion criteria. Tabulation: Table 1 presents the main characteristics and outcomes of the OC patients undergoing PIPAC. Integration: Study selection and data extraction were independently undertaken by two reviewers. Results: 235 patients from 15 studies retrieved from PubMed were included. Conclusions: Our results indicate that PIPAC is efficient and safe in selected OC patients with PC not responding to systemic chemotherapy. The toxicity is manageable and the quality of life sustained. Further, randomised controlled trials are warranted to confirm our findings.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treatment of advanced ovarian cancer. A review of the literature\",\"authors\":\"V. Psomiadou, A. Fotiou, A. Prodromidou, C. Iavazzo\",\"doi\":\"10.31083/j.ejgo4301004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: The majority of advanced ovarian cancer (OC) patients do not fully respond to systemic chemotherapy, thus complete cytoreduction can not be achieved in such cases. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been suggested as an alternative approach for these women. Our study aimed to review the literature regarding the application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in OC patients with peritoneal carcinomatosis (PC). Data source: Articles in the English language were searched in PubMed. Search terms included “PIPAC” and “ovarian cancer”. Methods of study selection: The authors evaluated all studies presenting an application of pressurised intraperitoneal aerosol chemotherapy (PIPAC) on ovarian cancer patients. The published guidelines for Systematic Reviews and Meta-analyses (PRISMA) were followed in the present systematic review which was performed based on the authors’ predetermined inclusion criteria. Tabulation: Table 1 presents the main characteristics and outcomes of the OC patients undergoing PIPAC. Integration: Study selection and data extraction were independently undertaken by two reviewers. Results: 235 patients from 15 studies retrieved from PubMed were included. Conclusions: Our results indicate that PIPAC is efficient and safe in selected OC patients with PC not responding to systemic chemotherapy. The toxicity is manageable and the quality of life sustained. Further, randomised controlled trials are warranted to confirm our findings.\",\"PeriodicalId\":11903,\"journal\":{\"name\":\"European journal of gynaecological oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-01-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of gynaecological oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.31083/j.ejgo4301004\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.ejgo4301004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：大多数晚期癌症（OC）患者对全身化疗没有完全反应，因此在这种情况下不能实现完全的细胞减少。加压腹膜内气雾剂化疗（PIPAC）已被建议作为这些妇女的替代方法。我们的研究旨在回顾关于加压腹膜内气雾剂化疗（PIPAC）在OC腹膜癌（PC）患者中的应用的文献。数据来源：PubMed检索到英文文章。搜索词包括“PIPAC”和“卵巢癌症”。研究选择方法：作者评估了所有在卵巢癌症患者中应用加压腹膜内气雾剂化疗（PIPAC）的研究。本系统综述遵循了已发表的系统综述和荟萃分析指南（PRISMA），该综述基于作者预先确定的纳入标准进行。表格：表1显示了接受PIPAC的OC患者的主要特征和结果。整合：研究选择和数据提取由两名评审员独立进行。结果：纳入了来自PubMed检索的15项研究的235名患者。结论：我们的研究结果表明，PIPAC在选择对全身化疗无反应的PC OC患者中是有效和安全的。毒性是可控的，生活质量是可持续的。此外，随机对照试验也证实了我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treatment of advanced ovarian cancer. A review of the literature

Objective: The majority of advanced ovarian cancer (OC) patients do not fully respond to systemic chemotherapy, thus complete cytoreduction can not be achieved in such cases. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been suggested as an alternative approach for these women. Our study aimed to review the literature regarding the application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in OC patients with peritoneal carcinomatosis (PC). Data source: Articles in the English language were searched in PubMed. Search terms included “PIPAC” and “ovarian cancer”. Methods of study selection: The authors evaluated all studies presenting an application of pressurised intraperitoneal aerosol chemotherapy (PIPAC) on ovarian cancer patients. The published guidelines for Systematic Reviews and Meta-analyses (PRISMA) were followed in the present systematic review which was performed based on the authors’ predetermined inclusion criteria. Tabulation: Table 1 presents the main characteristics and outcomes of the OC patients undergoing PIPAC. Integration: Study selection and data extraction were independently undertaken by two reviewers. Results: 235 patients from 15 studies retrieved from PubMed were included. Conclusions: Our results indicate that PIPAC is efficient and safe in selected OC patients with PC not responding to systemic chemotherapy. The toxicity is manageable and the quality of life sustained. Further, randomised controlled trials are warranted to confirm our findings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European journal of gynaecological oncology 医学-妇产科学

自引率

25.00%

发文量

审稿时长

1 months

期刊介绍： EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.